Targeting the mammalian target of rapamycin in myxoid chondrosarcoma

Anti-Cancer Drugs

Volumn 19, Issue 10, 2008, Pages 1019-1021

  Merimsky, Ofer ^a,b   Bernstein Molho, Rinat ^a   Sagi Eisenberg, Ronit ^a  

^a TEL AVIV UNIVERSITY   (Israel)

^b TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

Author keywords

Mammalian target of rapamycin; Myxoid chondrosarcoma; Rapamycin

Indexed keywords

5' METHYLTHIOADENOSINE PHOSPHORYLASE; CD99 ANTIGEN; CYCLIN D1; CYCLIN DEPENDENT KINASE; CYCLIN DEPENDENT KINASE 4; CYCLOPHOSPHAMIDE; GEMCITABINE; HISTONE DEACETYLASE; INTERSTITIAL COLLAGENASE; JUN N TERMINAL KINASE; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE; NAVELBINE; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN KINASE; PROTEIN KINASE C ALPHA; RAPAMYCIN; RETINOBLASTOMA PROTEIN; S6 KINASE; UNCLASSIFIED DRUG; VASCULOTROPIN A;

ADULT; ANTIANGIOGENIC ACTIVITY; ARTICLE; CANCER SURGERY; CASE REPORT; CHEMOTHERAPY; CHONDROSARCOMA; COUGHING; DISEASE COURSE; DYSPNEA; FEMALE; HUMAN; LUNG METASTASIS; METASTASIS; MYXOID CHONDROSARCOMA; PRIORITY JOURNAL; RADIOTHERAPY; THORACOTOMY; THORAX PAIN; TREATMENT RESPONSE; TUMOR GROWTH; TUMOR RECURRENCE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE NEOPLASMS; CHONDROSARCOMA; CYCLOPHOSPHAMIDE; FEMALE; HUMANS; MIDDLE AGED; PROTEIN KINASES; SIROLIMUS;

EID: 54249130444     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/CAD.0b013e328312c0e5     Document Type: Article

References (15)

1. Brennan M, Singer S, Maki RG, O'Sullivan B. Sarcomas of the Soft Tissues and Bone: section 1: soft tissue sarcoma. In: Vincent T, DeVita SH, Steven Rosenberg A, editors. Cancer Principles & Practice of Oncology Edition. Philadelphia: PA Lippincott Williams & Wilkins; 2000.
2. Chow WA. Update on chondrosarcomas. Curr Opin Oncol 2007; 19:371-376.
3. Brown RE, Boyle JL. Mesenchymal chondrosarcoma: molecular characterization by a proteomic approach, with morphogenic and therapeutic implications. Ann Clin Lab Sci 2003; 33:131-141.
4. Brown RE. Morphoproteomic portrait of the mTOR pathway in mesenchymal chondrosarcoma. Ann Clin Lab Sci 2004; 34:397-399.
5. Merimsky O. Targeting metastatic leiomyosarcoma by rapamycin plus gemcitabine: an intriguing clinical observation. Int J Mol Med 2004; 14:931-935.
6. Merimsky O, Gorzalczany Y, Sagi-Eisenberg R. Molecular impacts of rapamycin-based drug combinations: combining rapamycin with gemcitabine or imatinib mesylate (Gleevec) in a human leiomyosarcoma model. Int J Oncol 2007; 31:225-232.
7. Chen J, Zheng XF, Brown FJ, Schreiber SL. Identification of an 11-kDa FKBP12-rapamycin-binding domain within the 289-kDa FKBP12-rapamycin-associated protein and characterization of a critical serine residue. Proc Natl Acad Sci U S A 1995; 92:4947-4951.
8. Keith CT, Schreiber SL. PIK-related kinases: DNA repair, recombination, and cell cycle checkpoints. Science 1995; 270:50-51.
9. Huang S, Bjornsti MA, Houghton PJ. Rapamycins: mechanism of action and cellular resistance. Cancer Biol Ther 2003; 2:222-232.
10. Chen J. Novel regulatory mechanisms of mTOR signaling. Curr Top Microbiol Immunol 2004; 279:245-257.
11. Mita MM, Mita A, Rowinsky EK. Mammalian target of rapamycin: a new molecular target for breast cancer. Clin Breast Cancer 2003; 4:126-137.
12. Guba M, von Breitenbuch P, Steinbauer M, Koehl G, Flegel S, Hornung M, et al. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat Med 2002; 8:128-135.
13. Guba M, Koehl GE, Neppl E, Doenecke A, Steinbauer M, Schutt HJ, et al. Dosing of rapamycin is critical to achieve an optimal antiangiogenic effect against cancer. Transpl Int 2005; 18:89-94.
14. Oh CD, Kim SJ, Ju JW, Song WK, Kim JH, Yoo YJ, Chun JS. Immunosuppressant rapamycin inhibits protein kinase C alpha and p38 mitogen-activated protein kinase leading to the inhibition of chondrogenesis. Eur J Pharmacol 2001; 427:175-185.
15. Ishizuka T, Sakata N, Johnson GL, Gelfand EW, Terada N. Rapamycin potentiates dexamethasone-induced apoptosis and inhibits JNK activity in lymphoblastoid cells. Biochem Biophys Res Commun 1997; 230:386-391.